Other combinatorial treatments assessed in preclinical settings included JQ1, CPI0610, ABBV-075, MK-8628/OTX015, and I-BET762 in association with and the HDAC inhibitors vorinostat and romidepsin, or the BCL-2 inhibitor venetoclax, in preclinical models of cutaneous T-cell lymphoma (CTCL) including patient-derived primary samples and CTCL cell lines [87]. The gene discussed is BCL2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.